Trial Profile
To assess safety and efficacy of Ceftolozane/Tazobactam (TOL/TAZ) in children with Carbapenem-Resistant Pseudomonas Infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; Therapeutic Use
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018